J. Swoboda, Kathryn B. Scott, Charles O. Crawford, Thomas R. Simard, Louise P. Reyna, Sandra J. Krosschell, Kristin Acsadi, Gyula Elsheik, Bakri K. Schroth, Mary D'Anjou, Guy LaSalle, Bernard W. Prior, Thomas L. Sorenson, Susan Anne Maczulski, Jo B. Bromberg, Mark M. Chan, Gary T. Kissel, John CMAP values by treatment arm – 6 month values and change from baseline. 1<p> =  placebo group received matched placebo for both medications, L-carnitine and VPA.</p>2<p> = active treatment group received both L-carnitine and VPA.</p><p>*Difference  = 0.121. Upper confidence level difference 0.568. Lower confidence level difference −0.328.</p><p>**Difference  = 0.570. Upper confidence level difference 1.465. Lower confidence level difference −0.326.</p> genetics and genomics/medical genetics;genetics and genomics/pharmacogenomics;neurological disorders/neuromuscular diseases;pediatrics and child health/developmental and pediatric neurology 2010-08-19
    https://plos.figshare.com/articles/dataset/_CMAP_values_by_treatment_arm_8211_6_month_values_and_change_from_baseline_/505775
10.1371/journal.pone.0012140.t005